Targeting the trimolecular complex

Clinical Immunology

Volumn 149, Issue 3, 2013, Pages 339-344

  Michels, Aaron W ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Antigen presentation; Autoimmunity; ; Autoreactive T cells; ; Diabetes; ; Immune therapies; ; Insulin;

Indexed keywords

ARGININE; ASPARTIC ACID; CD4+ T LYMPHOCYTE RECEPTOR; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; INSULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; SELF PEPTIDE; SERINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ALPHA CHAIN; AMINO ACID SUBSTITUTION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; DISEASE PREDISPOSITION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

ANTIGEN PRESENTATION; AUTOIMMUNITY;; AUTOREACTIVE T CELLS;; DIABETES;; IMMUNE THERAPIES;; INSULIN;; NOD; NONOBESE DIABETIC MOUSE.; T CELL RECEPTOR; T1D; TCR; TYPE 1 DIABETES;

AMINO ACID MOTIFS; ANTIBODIES, MONOCLONAL; AUTOANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MOLECULAR SEQUENCE DATA; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL;

EID: 84887025779     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.02.020     Document Type: Review

References (40)

1. Todd J.A. Etiology of type 1 diabetes. Immunity 2010, 32:457-467.
2. Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300.
3. Bingley P.J. Clinical applications of diabetes antibody testing. J. Clin. Endocrinol. Metab. 2010, 95:25-33.
4. Steck A.K., Johnson K., Barriga K.J., Miao D., Yu L., Hutton J.C., Eisenbarth G.S., Rewers M.J. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care 2011, 34:1397-1399.
5. Harjutsalo V., Podar T., Tuomilehto J. Cumulative incidence of type 1 diabetes in 10,168 siblings of Finnish young-onset type 1 diabetic patients. Diabetes 2005, 54:563-569.
6. Harjutsalo V., Sjoberg L., Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008, 371:1777-1782.
7. Patterson C.C., Dahlquist G.G., Gyurus E., Green A., Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009, 373:2027-2033.
8. Michels A.W., Eisenbarth G.S. Immune intervention in type 1 diabetes. Semin. Immunol. 2011, 23:214-219.
9. Stadinski B.D., Zhang L., Crawford F., Marrack P., Eisenbarth G.S., Kappler J.W. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10978-10983.
10. + T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16729-16734.
11. Nakayama M., Castoe T., Sosinowski T., He X., Johnson K., Haskins K., Vignali D.A., Gapin L., Pollock D., Eisenbarth G.S. Germline TRAV5D-4 T-cell receptor sequence targets a primary insulin peptide of NOD mice. Diabetes 2012, 61:857-865.
12. Erlich H., Valdes A.M., Noble J., Carlson J.A., Varney M., Concannon P., Mychaleckyj J.C., Todd J.A., Bonella P., Fear A.L., Lavant E., Louey A., Moonsamy P. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008, 57:1084-1092.
13. Concannon P., Rich S.S., Nepom G.T. Genetics of type 1A diabetes. N. Engl. J. Med. 2009, 360:1646-1654.
14. McFarland B.J., Beeson C. Binding interactions between peptides and proteins of the class II major histocompatibility complex. Med. Res. Rev. 2002, 22:168-203.
15. Corper A.L., Stratmann T., Apostolopoulos V., Scott C.A., Garcia K.C., Kang A.S., Wilson I.A., Teyton L. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 2000, 288:505-511.
16. Lee K.H., Wucherpfennig K.W., Wiley D.C. Structure of a human insulin peptide/HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat. Immunol. 2001, 2:501-507.
17. Quartey-Papafio R., Lund T., Chandler P., Picard J., Ozegbe P., Day S., Hutchings P.R., O'Reilly L., Kioussis D., Simpson E., et al. Aspartate at position 57 of nonobese diabetic I-Ag7 beta-chain diminishes the spontaneous incidence of insulin-dependent diabetes mellitus. J. Immunol. 1995, 154:5567-5575.
18. Nakayama M., Abiru N., Moriyama H., Babaya N., Liu E., Miao D., Yu L., Wegmann D.R., Hutton J.C., Elliott J.F., Eisenbarth G.S. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435:220-223.
19. Nakayama M., Beilke J.N., Jasinski J.M., Kobayashi M., Miao D., Li M., Coulombe M.G., Liu E., Elliott J.F., Gill R.G., Eisenbarth G.S. Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J. Clin. Invest. 2007, 117:1835-1843.
20. Michels A.W., Nakayama M. The anti-insulin trimolecular complex in type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:329-334.
21. Gras S., Kjer-Nielsen L., Burrows S.R., McCluskey J., Rossjohn J. T-cell receptor bias and immunity. Curr. Opin. Immunol. 2008, 20:119-125.
22. Kobayashi M., Jasinski J., Liu E., Li M., Miao D., Zhang L., Yu L., Nakayama M., Eisenbarth G.S. Conserved T cell receptor alpha-chain induces insulin autoantibodies. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10090-10094.
23. Zhang L., Jasinski J.M., Kobayashi M., Davenport B., Johnson K., Davidson H., Nakayama M., Haskins K., Eisenbarth G.S. Analysis of T cell receptor beta chains that combine with dominant conserved TRAV5D-4*04 anti-insulin B:9-23 alpha chains. J. Autoimmun. 2009, 33:42-49.
24. Michels A.W., Ostrov D.A., Zhang L., Nakayama M., Fuse M., McDaniel K., Roep B.O., Gottlieb P.A., Atkinson M.A., Eisenbarth G.S. Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. J. Immunol. 2011, 187:5921-5930.
25. Hetherington S., Hughes A.R., Mosteller M., Shortino D., Baker K.L., Spreen W., Lai E., Davies K., Handley A., Dow D.J., Fling M.E., Stocum M., Bowman C., Thurmond L.M., Roses A.D. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002, 359:1121-1122.
26. Ostrov D.A., Grant B.J., Pompeu Y.A., Sidney J., Harndahl M., Southwood S., Oseroff C., Lu S., Jakoncic J., de Oliveira C.A., Yang L., Mei H., Shi L., Shabanowitz J., English A.M., Wriston A., Lucas A., Phillips E., Mallal S., Grey H.M., Sette A., Hunt D.F., Buus S., Peters B. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:9959-9964.
27. Illing P.T., Vivian J.P., Dudek N.L., Kostenko L., Chen Z., Bharadwaj M., Miles J.J., Kjer-Nielsen L., Gras S., Williamson N.A., Burrows S.R., Purcell A.W., Rossjohn J., McCluskey J. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012, 486:554-558.
28. Zhang L., Stadinski B.D., Michels A., Kappler J.W., Eisenbarth G.S. Immunization with an insulin peptide-MHC complex to prevent type 1 diabetes of NOD mice. Diabetes Metab. Res. Rev. 2011, 27:784-789.
29. Michels A.W., von H.M. Update: antigen-specific therapy in type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18(2011):235-240.
30. Daniel C., Weigmann B., Bronson R., von B.H. Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. J. Exp. Med. 2011, 208:1501-1510.
31. Mordes J.P., Bortell R., Blankenhorn E.P., Rossini A.A., Greiner D.L. Rat models of type 1 diabetes: genetics, environment, and autoimmunity. ILAR J. 2004, 45:278-291.
32. Mordes J.P., Cort L., Norowski E., Leif J., Fuller J.M., Lernmark A., Greiner D.L., Blankenhorn E.P. Analysis of the rat Iddm14 diabetes susceptibility locus in multiple rat strains: identification of a susceptibility haplotype in the Tcrb-V locus. Mamm. Genome 2009, 20:162-169.
33. Liu Z., Cort L., Eberwine R., Herrmann T., Leif J.H., Greiner D.L., Yahalom B., Blankenhorn E.P., Mordes J.P. Prevention of type 1 diabetes in the rat with an allele-specific anti-T-cell receptor antibody: Vbeta13 as a therapeutic target and biomarker. Diabetes 2012, 61:1160-1168.
34. Herold K.C., Hagopian W., Auger J.A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S.E., Harlan D.M., Xu D., Zivin R.A., Bluestone J.A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 2002, 346:1692-1698.
35. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., Schandene L., Crenier L., De Block C., Seigneurin J.M., De Pauw P., Pierard D., Weets I., Rebello P., Bird P., Berrie E., Frewin M., Waldmann H., Bach J.F., Pipeleers D., Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005, 352:2598-2608.
36. Sherry N., Hagopian W., Ludvigsson J., Jain S.M., Wahlen J., Ferry R.J., Bode B., Aronoff S., Holland C., Carlin D., King K.L., Wilder R.L., Pillemer S., Bonvini E., Johnson S., Stein K.E., Koenig S., Herold K.C., Daifotis A.G. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497.
37. Herold K.C., Gitelman S.E., Willi S.M., Gottlieb P.A., Waldron-Lynch F., Devine L., Sherr J., Rosenthal S.M., Adi S., Jalaludin M.Y., Michels A.W., Dziura J., Bluestone J.A. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013, 56:391-400.
38. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M., Raskin P., Rodriguez H., Schatz D.A., Wherrett D., Wilson D.M., Lachin J.M., Skyler J.S. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
39. Yu L., Herold K., Krause-Steinrauf H., McGee P.L., Bundy B., Pugliese A., Krischer J., Eisenbarth G.S. Rituximab selectively suppresses specific islet antibodies. Diabetes 2011, 60:2560-2565.
40. Orban T., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., Gottlieb P.A., Greenbaum C.J., Marks J.B., Monzavi R., Moran A., Raskin P., Rodriguez H., Russell W.E., Schatz D., Wherrett D., Wilson D.M., Krischer J.P., Skyler J.S. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.